The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Hurdles and opportunities in CAR T-cell therapies for lung cancer
Salman Punekar, MD, NYU Langone, New York, NY, comments on the challenges of CAR T-cell therapy for solid tumors, highlighting the need for a logic-gated approach to identify the right target and the difficulty of delivering CAR T-cells into the tumor microenvironment. These challenges are significant hurdles to overcome in order to effectively treat solid tumors. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
CAR T cells or solid tumor cell therapy in general for solid tumors has been plagued with a lot of difficulties. Difficulty probably stems from having the right target, which is why in EVEREST-2 we use a logic-gated approach. Another difficulty is actually getting the CAR T cells into the tumor microenvironment, which is a huge issue.
This transcript is AI-generated...
CAR T cells or solid tumor cell therapy in general for solid tumors has been plagued with a lot of difficulties. Difficulty probably stems from having the right target, which is why in EVEREST-2 we use a logic-gated approach. Another difficulty is actually getting the CAR T cells into the tumor microenvironment, which is a huge issue.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
